

MINIMALLY INVASIVE ROBOTIC LASER THERMOTHERAPY

**NeuroBlate®**  
SYSTEM



2020  
REIMBURSEMENT  
SUMMARY

## ICD-10-CM PROCEDURE CODES

Procedure Code	Descriptor	O.R.	MDC	MS-DRGs
<b>D0Y0KZZ</b>	Laser Interstitial Thermal Therapy of Brain	Y	1	023, 024, 025, 026, or 027
<b>D0Y1KZZ</b>	Laser Interstitial Thermal Therapy of Brain Stem	Y	1	025, 026, or 027

### NOTES:

- O.R. = Operating Room
- MDC = Major Diagnostic Category

## ICD-10-CM DIAGNOSIS CODES

Diagnosis Code	Descriptor
<b>C71.0</b>	Malignant Neoplasm of Cerebrum Except Lobes and Ventricles
<b>C71.1</b>	Malignant Neoplasm of Frontal Lobe
<b>C71.2</b>	Malignant Neoplasm of Temporal Lobe
<b>C71.3</b>	Malignant Neoplasm of Parietal Lobe
<b>C71.4</b>	Malignant Neoplasm of Occipital Lobe
<b>C71.5</b>	Malignant Neoplasm of Cerebral Ventricle
<b>C71.6</b>	Malignant Neoplasm of Cerebellum
<b>C71.7</b>	Malignant Neoplasm of Brain Stem
<b>C71.8</b>	Malignant Neoplasm of Overlapping Sites of Brain
<b>C71.9</b>	Malignant Neoplasm of Brain Unspecified
<b>C79.31</b>	Secondary Malignant Neoplasm of Brain
<b>G40.011</b>	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus
<b>G40.019</b>	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus
<b>G40.109</b>	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus
<b>G40.111</b>	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus
<b>G40.119</b>	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus
<b>G40.211</b>	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus
<b>G40.219</b>	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus

## MEDICARE SEVERITY DIAGNOSIS-RELATED GROUPS MS-DRGs ASSIGNMENT

MS-DRG	Descriptor
023	Craniotomy with Major Device Implant/Acute Complex Central Nervous System Principal Diagnosis with MCC or Chemo Implant or Epilepsy with Neurostimulator
024	Craniotomy with Major Device Implant/Acute Complex Central Nervous System Principal Diagnosis without MCC
025	Craniotomy and Endovascular Intracranial Procedures with MCC
026	Craniotomy and Endovascular Intracranial Procedures with CC
027	Craniotomy and Endovascular Intracranial Procedures without CC/MCC

### NOTES:

- MCC = Major Complications and Comorbidities
- CC = Complications and Comorbidities
- The MS-DRG assignment is based on the principle diagnosis and principle procedure code. For example, a patient with a principle diagnosis of malignant neoplasm of frontal lobe (ICD-10-CM diagnosis code C71.1) and receives LITT (ICD-10-PCS procedure code D0Y0KZZ), may be assigned to either MS-DRG 023, 024, 025, 026 or 027, depending on the secondary diagnosis
- The NeuroBlate® System is a tool (as opposed to a "treatment") that can be used by physicians to ablate tumors and epileptic foci. Physicians should use their clinical judgment and experience when deciding to use the NeuroBlate® System
- For coverage information and payment determination by private insurer, please contact individual insurer

## CURRENT PROCEDURAL TERMINOLOGY (CPT CODE)

CPT	Descriptor	Professional Component
64999	Unlisted Procedure, Nervous System	By Report

### NOTES:

- CPT = AMA Procedure Code indicating what procedure was performed.
- Descriptor = CPT descriptor of the procedure performed.
- CPT® 2020, CPT Copyright 2019 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.
- By Report = Payment for miscellaneous/unlisted codes are based upon detailed operative notes submitted by the physician.

The information provided contains general reimbursement information only and is not legal advice nor is it advice about how to code, complete, or submit any particular claim for payment. Information provided is not intended to increase or maximize reimbursement by any payer. The information provided represents Monteris' understanding of current reimbursement policies. It is the responsibility of the hospital and physician to determine appropriate codes, charges, and modifiers, and submit bills for the services consistent with the patient insurer requirements. Third-party payers may have different policies and coding requirements. Such policies can change over time. Monteris disclaims any responsibility for claims submitted by hospitals or physicians. Hospitals and physicians should check and verify current policies and requirements with the payer for any particular patient that will be treated using Monteris products. Monteris is available to help in this process. The key in all coding and billing to payers is to be truthful and not misleading and make full disclosures to the payer in all attempts to seek reimbursement for any product or procedure.

[Contact Monteris Medical Corporation for more information.](#)

[Not available for sale outside the U.S. or Canada.](#)

#### DISCLOSURES:

The NeuroBlate® System is intended for ablating intracranial soft tissue, including brain structures. Patients must be able to undergo MRI exposure and be surgical candidates. The technology is not appropriate for every lesion type and location. It may be difficult to use the technology on certain large or irregularly shaped lesions.

All brain surgeries carry risk. Possible adverse events include, but are not limited to, hematoma, embolic events, edema, bleeding, unintended major tissue damage and permanent neurological deficits. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. For full prescribing information, please visit [monteris.com](http://monteris.com).

#### U.S. Office

14755 27th Ave. N., Suite C  
Plymouth, MN 55447, USA  
+1.866.799.7655

#### Canadian Office

Unit 1B-25 Scurfield Blvd.  
Winnipeg, MB R3Y1G4, Canada  
+1.204.272.2220

[monteris.com](http://monteris.com)

Rx Only

©2020 Monteris. All Rights Reserved. ™ and ® denote Trademarks and Registered Trademarks of Monteris Medical Corporation.



AA10042 Rev G 06/20